<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129865</url>
  </required_header>
  <id_info>
    <org_study_id>LYT-300-2021-101</org_study_id>
    <nct_id>NCT05129865</nct_id>
  </id_info>
  <brief_title>LYT-300 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LYT-300 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PureTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PureTech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the&#xD;
      safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300.&#xD;
&#xD;
      Part 2 is a crossover assessment in HV of the effects of food on the safety, tolerability,&#xD;
      and PK profile of orally administered LYT-300.&#xD;
&#xD;
      Part 3 is a multiple ascending dose (MAD) trial in HV to assess the safety, tolerability, and&#xD;
      PK profile of multiple doses (up to 7 days) of orally administered LYT-300.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: This is a randomized, double-blind, placebo-controlled, SAD design to assess the&#xD;
      safety, tolerability, and PK profile of orally administered LYT-300 in HV, in a 3-period,&#xD;
      3-sequence, crossover, dose escalation design.&#xD;
&#xD;
      Part 2: This is a randomized, open label, 2-period, 2-sequence, crossover assessment of the&#xD;
      effects of food on the PK, safety, and tolerability of orally administered LYT-300 in HV. A&#xD;
      single dose of LYT-300 will be administered on 2 occasions, separated by a minimum 7-day&#xD;
      washout period. Part 2 is planned as a single dosing cohort.&#xD;
&#xD;
      Part 3: This is a randomized, double-blind, placebo-controlled, sequential, MAD trial in HV&#xD;
      to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally&#xD;
      administered LYT-300. This part will include ascending doses given either once daily in the&#xD;
      morning (QAM), once daily in the evening (QHS), or twice daily (BID).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 consists of 1 Arm with crossover of active treatment and placebo Part 2 consists of 1 Arm with active treatment Part 3 consists of 6 Arms with active treatment or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part 1 and Part 3 are double-blind during the data collection. Determination for dose escalation may be made under unblinded conditions by assessors.&#xD;
Part 2 is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: treatment-emergent adverse events [TEAEs]</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Evaluate the safety and tolerability in healthy volunteers following single or multiple oral doses of LYT-300 as measured by TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of food in healthy volunteers</measure>
    <time_frame>2 days (main time frame)</time_frame>
    <description>Measure concentration of allopregnanolone in blood plasma in fed or fasted subjects administered a single dose of LYT-300</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use pharmacokinetics to characterize the blood plasma concentration of allopregnanolone after administration of LYT-300</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Measure the blood plasma concentrations of allopregnanolone in healthy volunteers after single and multiple doses of LYT-300 administered up to 7 days</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Doses TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-300, Dose TBD with and without food, separated by 7-day washout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-300, Dose TBD QAM every 24 h for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QAM every 24 h for 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Dose TBD QAM or QHS every 24 h for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will crossover across 2 dosing periods in which they will receive LYT-300 Dose TBD QAM or QHS every 24 h for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QAM or QHS every 24 h for 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will crossover across 2 dosing periods in which they will Placebo QAM or QHS every 24 h for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Dose TBD BID every 12 h for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID every 12 h for 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-300</intervention_name>
    <description>A prodrug of allopregnanolone, a small molecule drug</description>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300</arm_group_label>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Dose TBD BID every 12 h for 7 days</arm_group_label>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Dose TBD QAM or QHS every 24 h for 7 days</arm_group_label>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Doses TBD</arm_group_label>
    <arm_group_label>LYT-300, Dose TBD QAM every 24 h for 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for LYT-300</description>
    <arm_group_label>LYT-300 in healthy volunteers LYT-300, Doses TBD</arm_group_label>
    <arm_group_label>Placebo BID every 12 h for 7 days</arm_group_label>
    <arm_group_label>Placebo QAM every 24 h for 7 days</arm_group_label>
    <arm_group_label>Placebo QAM or QHS every 24 h for 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
        Parts 1, 2 and 3: Healthy Volunteers&#xD;
&#xD;
          1. Male or female between 18 and 55 years old (inclusive) at the time of screening.&#xD;
&#xD;
          2. In good general health at screening, free from clinically significant unstable&#xD;
             medical, surgical or psychiatric illness, at the discretion of the Investigator.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
        Parts 1, 2 and 3: Healthy Volunteers&#xD;
&#xD;
          1. Evidence or history of any condition or situation that adversely impacts a normal&#xD;
             sleep-wake cycle.&#xD;
&#xD;
          2. Confirmed COVID-19 infection within 6 months of screening, known exposure to another&#xD;
             person with COVID-19 within 14 days of screening&#xD;
&#xD;
          3. History of illness with fever within 28 days prior to the first dose.&#xD;
&#xD;
          4. A history of, or current evidence for, serious mental illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Paden</last_name>
    <phone>617-456-0367</phone>
    <email>clinicaltrials@puretechhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Bonner</last_name>
    <phone>617-456-0367</phone>
    <email>clinicaltrials@puretechhealth.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 31, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

